Liang Zhang*, Ligen Zhang
Department of Breast, Thyroid, and Vascular Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, China.
*Corresponding author: Liang Zhang
Abstract
Objective: To evaluate the efficacy of epirubicin and cyclophosphamide combined with albumin-bound paclitaxel in the treatment of breast cancer. Methods: A total of 289 patients diagnosed with breast cancer (admitted between January 2022 and 2024) were enrolled as study subjects. Using a random number table, patients were divided into a control group (n=144) and an observation group (n=145). The control group received the chemotherapy regimen of epirubicin, cyclophosphamide, and docetaxel, while the observation group received the regimen of epirubicin, cyclophosphamide, and albumin-bound paclitaxel. The therapeutic outcomes and incidence of adverse reactions were compared between the two groups. Results: The observation group demonstrated a higher overall response rate and a lower overall incidence of adverse reactions compared to the control group (P<0.05). Conclusion: The chemotherapy regimen of epirubicin, cyclophosphamide, and albumin-bound paclitaxel enhances clinical efficacy and reduces the risk of adverse reactions in breast cancer patients.
References
[1] Wang HM, Yu AY, Li LL, et al. Clinicopathological features, psychological status, and prognosis of 33 patients with occult breast cancer. World J Psychiatry. 2024;14(1):76-87.
[2] Chen JY, Li JD, He RQ, et al. Bibliometric analysis of phosphoglycerate kinase 1 expression in breast cancer and its distinct upregulation in triple-negative breast cancer. World J Clin Oncol. 2024;15(7):867-94.
[3] Liang Y. Clinical Analysis of Trastuzumab-Targeted and Chemotherapy Treatment for Breast Cancer Patients. Proc Anticancer Res. 2024;8(6):73-9.
[4] Peng JY, Wu S, Luo J. Efficacy and quality of life impact of docetaxel combined with liposomal doxorubicin and cyclophosphamide in the treatment of HER-2-negative breast cancer. Clin Ration Drug Use. 2023;16(27):115-8.
[5] Wang HR, Zhao HQ, Li CY. Effectiveness of albumin-bound paclitaxel, cyclophosphamide, and epirubicin combined chemotherapy in advanced breast cancer treatment. Clin Med. 2024;44(7):89-91.
[6] Department of Medical Administration, Ministry of Health of the People’s Republic of China. Guidelines for the Diagnosis and Treatment of Breast Cancer (2011 Edition). Chin J Pract Surg. 2011;31(10):902-7.
[7] Feng FY. New criteria for evaluating the efficacy of solid tumors (interpretation of the RECIST 1.1 standard). In: Proceedings of the 3rd China Congress of Medical Oncology; 2009:123-5.
[8] Zhang M, Zhang DJ. Evaluation of efficacy and safety of albumin-bound paclitaxel combined with epirubicin and cyclophosphamide in neoadjuvant chemotherapy for breast cancer. North Pharm. 2023;20(12):92-4.
[9] Lu CN, Gao XB, Li F. Therapeutic efficacy of albumin-bound paclitaxel combined with cyclophosphamide and doxorubicin in neoadjuvant chemotherapy for breast cancer. Shenzhen J Integr Tradit Chin West Med. 2023;33(13):79-81.
[10] Chen J, Lei W, Lin QZ, et al. Clinical application of epirubicin, cyclophosphamide combined with albumin-bound paclitaxel in breast cancer patients. Chin J Med Res. 2023;21(30):5-9.
How to cite this paper
Effect Analysis of Paclitaxel, Cyclophosphamide Combined with Albumin-paclitaxel in the Treatment of Breast Cancer
How to cite this paper: Liang Zhang, Ligen Zhang. (2026) Effect Analysis of Paclitaxel, Cyclophosphamide Combined with Albumin-paclitaxel in the Treatment of Breast Cancer. International Journal of Clinical and Experimental Medicine Research, 10(3), 223-226.
DOI: http://dx.doi.org/10.26855/ijcemr.2026.05.011